However, a post hoc analysis revealed a potential beneficial effect of NAC in a subgroup of individuals carrying a specific genetic variant, TOLLIP rs3750920 TT genotype, present in about 25% of patients with IPF. The gene discussed is TOLLIP; the disease is idiopathic pulmonary fibrosis.